One of the knocks against using nirmatrelvir-ritonavir (Paxlovid) to treat patients with SARS-CoV-2 has been that it could send patients running to the emergency room, and possibly face hospitalization, for rebound COVID-19. It’s enough to discourage some people from taking it, even if they’re high risk for poor outcomes with COVID. According to a report from the Centers for Disease Control and Prevention, however, those patients should be more concerned about the consequences of not …
Read More









